Firm’s mass spec systems will be leveraged to analyze cancer cell lines.

Thermo Fisher Scientific is collaborating with the University Health Network (UHN) related to cancer biomarker development. The UHN team will use the company’s LTQ Orbitrap™ and Quantum Ultra™ mass spectrometry systems.

Thermo Fisher Scientific and the UHN will also maintain a cross-validation workflow to help legitimize new biomarkers. After the UHN team validates a cancer biomarker, they will send it to the Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry Center for a second validation.

The researchers will look for proteins in the secreted fluids of cancer cell lines. The partners believe that this approach will accelerate the validation of biomarkers, targeted assays, and ultimately the development of blood tests.

Previous articleImmuneRegen’s Adjuvant to Be Tested with the Biodesign Institute’s Vaccine against Norwalk Viruses
Next articleResearchers Link Two Gene Variants that Control Ion Channels to Bipolar Disorder